Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2026-04-01 Epub Date: 2026-03-23 DOI:10.1016/j.gore.2026.102070

Alice P. Barr, Ngoctran Nakamura, Nancy T. Nguyen

{"title":"Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report","authors":"Alice P. Barr, Ngoctran Nakamura, Nancy T. Nguyen","doi":"10.1016/j.gore.2026.102070","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Vulvar adenocarcinoma represents a rare subset of gynecologic malignancies, with limited therapeutic options in the advanced or recurrent setting. HER2 testing is not routinely performed on vulvar carcinoma.</div></div><div><h3>Case presentation</h3><div>We report the case of a 69-year-old woman diagnosed with human epidermal growth factor 2 (HER2)-amplified recurrent metastatic vulvar adenocarcinoma arising in the context of extramammary Paget’s disease. Despite multiple standard systemic therapies, she experienced marked disease with diffuse metastases. With subsequent trastuzumab deruxtecan (T-Dxd) treatment, she achieved a complete and durable response and remains with no evidence of disease after one year of follow-up.</div></div><div><h3>Conclusion</h3><div>This report underscores the potential utility of HER2-directed therapy in select cases of vulvar carcinoma and emphasizes the importance of molecular profiling in rare gynecologic neoplasms.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"64 ","pages":"Article 102070"},"PeriodicalIF":1.3000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578926000500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Vulvar adenocarcinoma represents a rare subset of gynecologic malignancies, with limited therapeutic options in the advanced or recurrent setting. HER2 testing is not routinely performed on vulvar carcinoma.

Case presentation

We report the case of a 69-year-old woman diagnosed with human epidermal growth factor 2 (HER2)-amplified recurrent metastatic vulvar adenocarcinoma arising in the context of extramammary Paget’s disease. Despite multiple standard systemic therapies, she experienced marked disease with diffuse metastases. With subsequent trastuzumab deruxtecan (T-Dxd) treatment, she achieved a complete and durable response and remains with no evidence of disease after one year of follow-up.

Conclusion

This report underscores the potential utility of HER2-directed therapy in select cases of vulvar carcinoma and emphasizes the importance of molecular profiling in rare gynecologic neoplasms.

查看原文本刊更多论文

曲妥珠单抗对her2扩增的侵袭性外阴腺癌的完全和持久的反应：一个病例报告

背景外阴腺癌是一种罕见的妇科恶性肿瘤，在晚期或复发时治疗选择有限。HER2检测不常用于外阴癌。我们报告一例69岁的女性被诊断为人类表皮生长因子2 （HER2）扩增的复发转移性外阴腺癌，发生在乳腺外佩吉特病的背景下。尽管进行了多种标准的全身治疗，但她的病情仍有明显的弥漫性转移。在随后的曲妥珠单抗德鲁德康（T-Dxd）治疗中，她获得了完全和持久的缓解，并在随访一年后仍无疾病迹象。结论本报告强调了her2靶向治疗外阴癌的潜在效用，并强调了分子谱分析在罕见妇科肿瘤中的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.